Unfortunately, only one other phase I clinical trial utilizing MV-CEA has been completed in patients with recurrent glioblastoma (NCT00390299) and there is no ongoing studies utilizing MV-CEA, thus its immune regulatory properties will likely remain unknown. Here, CEACAM5 is linked to glioblastoma.